Nevertheless, our analysis provides evidence to support the pharmacodynamic effect of myostatin inhibition in patients with DMD as measured by DXA, which, unfortunately, was not sufficient to translate into consistent functional improvements. Here, MSTN is linked to Duchenne muscular dystrophy.